IAS 2017 Karine Lacombe of Saint-Antoine Hospital, Paris, at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com Hepatitis C treatmentHepatitis C treatment is effective and feasible in Africa Dzintars Gotham presenting at IAS 2017. Image credit: Enzo Poultreniez / http://aides.org$90-$90-$90 targetCountries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Karine Lacombe at IAS 2017. Photo by Steve Forrest/Workers' Photos/IASTreatment for people with HIV/HCV co-infectionGlecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection infohep news Fibrosis People with HIV are at risk for liver fibrosis and steatosis Michael Carter / 21 August 2017 Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ... Pharmaceutical industry Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... Treatment for people living with HIV and HCV Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Access to medicines & diagnostics Hepatitis C treatment is effective and feasible in Africa Liz Highleyman / 25 July 2017 Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to a presentation yesterday at the ... View more > Editors' picks from other sources View more > Other pages in this section Latest news All the news Conference news Email bulletin archive